EUVIMED · CrossrefZeitschrift
Hematological Oncology
ISSN 0278-0232 · Wiley
Neueste Artikel
Issue Information
Decision‐Making on First‐Line Treatment Alternatives in Chronic Lymphocytic Leukemia: A Multi‐Criteria Decision Analysis to Elicit Stakeholders' Preferences in Italy
Luspatercept in Myelodysplastic Syndromes With Ring Sideroblasts: Long Term Outcome and Impact on Non‐Erythroid Blood Counts
Therapeutic Approaches and Clinical Outcomes of Myeloid/Lymphoid Neoplasms With Eosinophilia Harboring FLT3 Rearrangements: A Systematic Review of 39 Cases
Baseline Spleen Volume is Independently Associated With Survival After CD19‐Directed Chimeric Antigen Receptor T‐Cell Therapy in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma
The Histone Lactylation of KREMEN2 Inhibits Ferroptosis Through the JAK2/STAT3/GPX4 Axis and Promotes the Progression of Mantle Cell Lymphoma
Temporal Trends in Real‐World Outcomes With CPX‐351 in Secondary/High‐Risk Acute Myeloid Leukemia: A PETHEMA Study
Macular OCTA Biomarkers of Ocular Involvement in Patients With Primary Central Nervous System Lymphoma
Extracorporeal Cytokine Hemadsorption for the Treatment of Severe Steroid Refractory Cytokine Release Syndrome Secondary to T‐Cell Immunotherapy for B‐Cell Malignancies: A Case Series
Cutting‐Edge Technologies to Decode Tumor Microenvironment in Multiple Myeloma
Longitudinal Monitoring of Measurable Residual Disease in Chronic Lymphocytic Leukemia Patients Treated With Venetoclax: Results of a Prospective Multicenter Real‐Life Study
Efficacy and Safety Comparisons of Four Approved Chimeric Antigen Receptor T‐Cell Therapies in Multiple Myeloma
Anatomical Localization–Based Analysis of Relapsed Secondary Central Nervous System Aggressive B‐Cell Lymphoma (R‐SCNSL)
Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third‐Line CAR T
TALOs, Fill the Gap: Tafasitamab and Lenalidomide in Diffuse Large B‐Cell Lymphoma in the Real‐Life Patient Journey
The French Experience of Pharmacists and CAR T‐Cells: A Study of the French Society of Oncology Pharmacy (SFPO)
Treatment‐Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De‐Escalation: 96‐Week Update of the DANTE Study
Current Status of Revisions to the Lugano Classification in Lymphoma
TP53 ‐Mutated Acute Myeloid Leukemia: Unanswered Questions
Risk Stratification for Diffuse Large B‐Cell Lymphoma by Integrating Interim 18 F‐FDG PET‐CT Analysis and the NCCN‐IPI: A Multicenter Retrospective Study
Multiple Myeloma Unpacked
122 | IDENTIFYING HARMFUL HYPERINFLAMMATION IN DIFFUSE LARGE B‐CELL LYMPHOMA USING THE OHI (OPTIMIZED HLH INFLAMMATORY) INDEX—DISCOVERY AND VALIDATION IN REAL‐WORLD PATIENTS
132 | CLINICAL IMPACT OF CLONAL AND SUBCLONAL DRIVER ALTERATIONS IN MANTLE CELL LYMPHOMA SUBTYPES
160 | VERLen: TAFASITAMAB, LENALINOMIDE, PLUS RITUXIMAB IN FRONTLINE DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS OVER 80 Y/O OR OLDER, A LYSA PHASE 2 TRIAL
69 | ESCAPE FROM CAR‐NEGATIVE ENDOGENOUS CD8 T CELLS DRIVES RESISTANCE TO CD19‐DIRECTED CAR‐T THERAPIES IN LARGE B‐CELL LYMPHOMAS
91 | BMS‐986458, A FIRST‐IN‐CLASS, BIFUNCTIONAL CEREBLON‐DEPENDENT LIGAND‐DIRECTED DEGRADER (LDD) OF B‐CELL LYMPHOMA 6 (BCL6) IN PATIENTS WITH R/R NHL: INITIAL PH 1 RESULTS
OT01 | A PHASE 3 TRIAL OF OBINUTUZUMAB AND VENETOCLAX WITH OR WITHOUT ACALABRUTINIB IN PATIENTS WITH HIGH RISK CHRONIC LYMPHOCYTIC LEUKEMIA: CLL16 TRIAL OF THE GCLLSG
210 | REAL‐WORLD COMPARATIVE EFFECTIVENESS OF FIRST‐LINE BRUTON TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
233 | S1608: RANDOMIZED PHASE II TRIAL COMPARING LENALIDOMIDE/OBINUTUZUMAB AND UMBRALISIB/OBINUTUZUMAB WITH CHEMOIMMUNOTHERAPY IN EARLY PROGRESSING FOLLICULAR LYMPHOMA (POD24)
444 | A PHASE 1 STUDY OF SGR‐1505, AN ORAL, POTENT MALT1 INHIBITOR FOR R/R B‐CELL MALIGNANCIES, INCLUDING CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)
Jahrgänge
2026 · 1172025 · 1.0682024 · 1122023 · 8602022 · 1302021 · 5262020 · 1142019 · 6912018 · 1292017 · 6712016 · 382015 · 752014 · 442013 · 722012 · 432011 · 432010 · 322009 · 352008 · 482007 · 322006 · 372005 · 212004 · 182003 · 212002 · 162001 · 292000 · 231999 · 181998 · 341997 · 421996 · 511995 · 421994 · 381993 · 521992 · 541991 · 641990 · 581989 · 681988 · 561987 · 49
EUVIMED